SRX251

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

SRX251, or SRX-251, also known as API-251, is a selective vasopressin V 1A receptor antagonist that is or was under development for the treatment of aggression. It was also being developed for the treatment of dysmenorrhea, but development for this indication was discontinued. The drug is taken by mouth. SRX251 reduces aggressive behavior in rodents. It is or was being developed by Azevan Pharmaceuticals. In 2007, it was in phase 1 clinical trials.

SRX251, or SRX-251, also known as API-251, is a selective vasopressin V 1A receptor antagonist that is or was under development for the treatment of aggression. It was also being developed for the treatment of dysmenorrhea, but development for this indication was discontinued. The drug is taken by mouth. SRX251 reduces aggressive behavior in rodents. It is or was being developed by Azevan Pharmaceuticals. In 2007, it was in phase 1 clinical trials.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1372051975 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

2 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.